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The concept of pathotype in Marek’s disease (MD) probably dates from the recognition of a more virulent 
form of the disease in the late 1950s (Benton & Cover, 1957). Distinctions between MD virus strains were 
further expanded with the description of the vv pathotype in the early 1980s and of the vv+ pathotype in the 
1990s. Pathotype designations reflect important biological properties that correlate with the break-through 
of vaccinal immunity in the field. However, pathotyping methods applied by various laboratories have not 
been uniform, preventing critical comparison of results. Better uniformity of pathotyping procedures is 
desirable.
The Avian Disease and Oncology Laboratory (ADOL) method is based on induction of lymphoproli­
ferative lesions in vaccinated chickens. This method has been used to pathotype more than 45 isolates and is 
the basis for the current pathotype classification of MD virus strains. Its limitations include requirements for 
a specific type of chickens (15 x 7 ab + ), large numbers of animals, and a statistical method to compare 
lesion responses to those of JM/102W and Md5 control strains. Because of these limitations, it has not been 
and is not likely to be used in other laboratories.
Comparability in pathotyping can be improved by the comparison of field isolates with standard 
prototype strains such as JM/102W, Md5 and 648A (American Type Culture Collection) or their equivalents. 
Data may be generated by different in vivo procedures that measure tumour induction, neurological disease 
(both neoplastic and non-neoplastic lesions), or solely non-neoplastic criteria (such as lymphoid organ 
weights or virus replication). Methods based on neoplastic criteria, especially when generated in MD- 
immunized chickens, will probably correlate most closely with that of the ADOL method and be most 
relevant to evolution of MD virus in the field. Based on data from several trials, a modification of the 
ADOL method that utilizes fewer chickens and can be conducted with commercial specific pathogen free 
strains is proposed. The modified method is based on “best fit” comparisons with prototype strains, and is 
expected to provide results generally comparable with the original method. A variety of other alternative 
criteria (see earlier*  are also evaluated both for primary pathotyping and as adjuncts to other pathotyping 
methods. Advantages and disadvantages of alternative methods are presented.
Introduction and History
Virulence is a property associated with those Marek’s 
disease viruses (MDVs) designated as serotype 1. Related 
herpesviruses of serotypes 2 and 3 are considered non- 
oncogenic. Virulence is usually measured in terms of the 
ability to induce lymphoproliferative lesions in chickens, 
normally characterized by enlargements of peripheral 
nerves due to lymphoid infiltration and lymphomas in 
various visceral organs or tissues. Virulence is important 
for many reasons, but especially because this property 
varies among serotype 1 MDV isolates and is directly 
related to the ability of isolates to be protected by 
vaccines. Also, virulence of MDV strains has increased 
over the years (Witter, 1997), a trend that continues to 
the present time and represents a formidable obstacle to 
the long-term control of the disease.
The term “pathotype”, although properly used to 
designate classes of organisms that induce different types 
of pathology, has in the case of Marek’s disease (MD) 
been widely applied to designate differences in the 
virulence of isolates as measured (primarily) by the 
frequency of disease induced. This reflects the practical 
importance of virulence, especially the ability to cause 
disease in immunized chickens, compared with other 
classification criteria. The use of “neuropathotype” to 
designate strains that induce distinctly different types of 
pathology in the central nervous system (Gimeno et al., 
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2002) is a more conventional application of pathotype 
terminology.
Soon after the development of reliable methods for its 
biological transmission (Sevoian et al., 1962; Biggs & 
Payne, 1963), variation in the virulence of MD strains 
became apparent. In what is probably the seminal 
observation, Biggs and coworkers reported that the 
newly isolated HPRS-16 and HPRS-18 strains induced 
higher mortality with shorter latent periods and more 
visceral lymphomas compared with the previously iso­
lated B14 strain (Biggs et al., 1965). These authors 
proposed that strains be classified as “classical” or 
“acute”, with the acute strains differentiated by the 
induction of higher morbidity and mortality, earlier 
onset, and a higher incidence of visceral tumours 
compared with classical strains. Interestingly, this first 
proposal for what was essentially a pathotypic classifica­
tion for MDV preceded by several years the isolation 
and identification of the aetiological agent of the disease. 
Use of this classification to type additional field isolates 
(Purchase & Biggs, 1967) reflected correctly a significant 
shift of virulence in MD that would be identified again in 
later classifications.
A set of criteria for differentiating between acute and 
classical strains on the basis of histological lesions in 
nerves and viscera was later described (Biggs & Milne, 
1972). Acute isolates had higher lesion scores (> 1.5) on 
a 1 to 5 scale than classical isolates (<1.5). Thus, 
classification was a product of both virulence and tissue 
tropism. Strains such as JM and GA differ greatly in 
tissue tropism but are equally virulent (Purchase et al., 
1971) and equally protected by herpesvirus of turkeys 
(HVT) vaccination: both are properly classified as acute 
strains. This suggests that virulence may be more reliable 
than tissue tropism as a criterion for classification, 
although the two parameters are often linked.
Important variation in virulence and induction of 
humoral immune responses was observed between the 
JM-10 and CU-2 isolates (Smith & Calnek, 1973) but no 
unique nomenclature was proposed, even though sub­
sequent work places these isolates in different patho- 
types.
A shift of virulence among MDV strains recognized in 
the late 1970s in association with an unexplained 
increase in MD losses in vaccinated flocks (Eidson et 
al., 1978) prompted further evolution in the process of 
pathotype identification. Witter et al. (1980) isolated 
and characterized several strains from Maryland that 
caused a higher frequency of MD lesions in HVT- 
vaccinated chickens than earlier isolates. These isolates 
were originally considered as “variant” viruses but later 
were termed very virulent or vvMDV (Witter, 1983) as a 
more appropriate way to distinguish these isolates from 
earlier virulent or vMDV strains. The initial method was 
based on the arbitrary criterion of HVT protection— 
isolates against which HVT provided 77% protection or 
less were considered as vv (Witter, 1983). Some labora­
tories applied vv nomenclature if the isolate caused 
significant disease in vaccinated chickens (Powell & 
Lombardini, 1986; Jurajda & Halouzka, 1988; 
Mckimm-Breschkin et al., 1990). In some cases, an 
isolate was termed “vv” pathotype for no reason other 
than it was derived from vaccinated flocks with excessive 
MD losses (Witter, 1988). In response, Witter modified 
the definition to the following: “vvMDV isolates are 
those which induce MD lesions in HVT-vaccinated, 
susceptible chickens at a rate greater than that of a 
prototype vMDV isolate, such as JM or GA” (Witter, 
1988). This helped to establish the important concept of 
pathotype determination based on comparison with a 
prototype strain.
This concept was soon adopted by several labora­
tories. Imai and coworkers (Imai & Yuasa, 1988; Imai et 
al., 1992) designated isolates as vv by multiple criteria, 
including a comparison with prototype vv strains Md5 
and RB1B. Buscaglia and coworkers typed isolates using 
P2a chickens in Argentina by comparison with control 
strains either from sister trials conducted in the United 
States (Buscaglia et al., 1995) or, later, with direct 
comparisons with the JM and RB1B strains (Buscaglia 
et al., 2004). Liu et al. (1996) typed isolates as vv by 
comparison with the control strain GA. The Cl2/130 
strain was identified as having special virulence proper­
ties by comparison with the prototype strain HPRS-16 
(Venugopal et al., 1996), although a pathotype designa­
tion was not applied in this work. Sung classified the 
KOMD-IC isolate as vv pathotype on the basis of 
comparisons with the JM strain (Sung, 2002). On the 
other hand, other reports have described what appear to 
be highly virulent isolates without benefit of a prototype 
virus control (Kross, 1996; Lin & Chen, 1996). The 
preceding authors were all working to characterize new 
MDV isolates and, in some cases, to assign pathotype 
designations. However, the procedures varied widely.
The driving force behind a pathotypic classification 
was the association of pathotype with the field disease. 
Each new pathotype appeared associated with a new 
wave of MD losses in commercial chicken flocks. Also, 
each pathotype appeared associated with the ability to be 
protected by specific MD vaccines. For example, v 
pathotype strains induced high levels of disease in non­
vaccinated chickens, but little disease in chickens vacci­
nated with HVT. In contrast, vv pathotype strains 
induced high levels of disease in HVT-vaccinated chick­
ens, but little disease in chickens vaccinated with bivalent 
vaccines composed of HVT and selected serotype 2 
strains such as SB-1 or 301B/1.
Thus, four pathotypes of serotype 1 MDV are 
currently recognized; m (mild), v, vv and vv+ (Witter, 
1997). Pathotype m includes strains previously termed as 
classical. However, no m pathotype strains have been 
recognized among recent isolates and the frequency of 
this pathotype in the field is uncertain.
Yet another wave of increased MD losses in vaccinated 
flocks was noted in the early 1990s, especially in the 
United States. Some of the isolates from such flocks 
caused higher frequencies of MD in bivalent-vaccinated 
chickens than did prototype vv pathotype strains such as 
Md5. Witter proposed that these strains may represent 
yet a new pathotype and proposed the designation 
“vv + ” (Witter, 1997). Once again, a new pathotype 
was associated with a change in field disease incidence 
and the failure of established vaccines to provide 
adequate protection.
The present Avian Disease and Oncology Laboratory 
(ADOL) method for determination of pathotype (Witter, 
1997), in use since approximately 1989, is based on the 
induction of lymphoproliferative lesions in vaccinated 
chickens (see later description). This method has been 
used to pathotype more than 45 isolates and can 
probably be considered as the gold standard for patho­
type classification of MDV strains. However, the re­
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quirement for a specific type of chicken (15 x 7 ab+) 
and the high cost of keeping large numbers of chickens 
through a 9-week experimental period have deterred use 
of this method by other laboratories. Consequently, 
isolates continue to be described where pathotyping 
data are insufficient to permit critical evaluation.
This problem is no doubt responsible for the recent 
introduction of the term “hypervirulent”, which has 
been used to designate serotype 1 field isolates (such as 
the Italian isolate, EU1, isolated in 1992) that induce 
tumours in CVI988-vaccinated chickens (Schumacher et 
al., 2002; Burgess, 2004). Such isolates had sufficient 
virulence to warrant a unique designation but could not 
be identified as vv + because formal pathotyping by the 
ADOL method was not available in European labora­
tories. Hypervirulent and vv+ designations should not 
be considered to be equivalent because no definitive 
criteria for classification of viruses as hypervirulent are 
available.
MD isolates that differ in ability to induce MD lesions 
in vaccinated chickens also tend to differ for additional 
biological characteristics. Compared with less virulent 
isolates, the more virulent isolates are generally consid­
ered to produce more visceral tumours with an earlier 
onset of tumour mortality, to cause disease in genetically 
resistant strains of chickens, to cause more immunode­
pression often associated with severe lytic changes in 
lymphoid organs, to induce early non-neoplastic death 
(early mortality syndrome), to induce more transient 
paralysis, and to replicate more rapidly and to higher 
titres in vivo. Some additional characteristics such as 
severe lytic infection (Kross, 1996; Venugopal et al., 
1996), severe proliferative lesions in the brain (Cho et al., 
1998), haemolytic anaemia (Gilka & Spencer, 1995), and 
tropism for monocytes (Barrow et al., 2003) have been 
associated with certain highly virulent strains, but are 
not necessarily associated with any of the designated 
pathotypes. Several of these characteristics have been 
proposed as alternative criteria for pathotyping.
In confirmation of earlier studies (Rivas & Fabricant, 
1988), Calnek et al. (1998) observed a correlation 
between pathotype and characteristics related to immu­
nodepression; that is, persistence of early cytolytic 
infection and atrophy of thymus and bursa of 
Fabricius—these workers proposed that measurement 
of lymphoid organ weights might be useful for classifica­
tion of MDV isolates by pathotype. Sung (2002) utilized 
bursal weight data in the pathotypic classification of a 
field isolate.
Based on the earlier observation that highly virulent 
MDV strains induced an acute form of transient 
paralysis (Witter et al., 1999), Gimeno et al. (2002) 
proposed a classification of MDV strains into three 
neuropathotypes. Although the neuropathotypes were 
correlated with virulence and pathotype, the relation­
ships were not perfect and this classification was 
considered an adjunct to rather than a replacement for 
conventional pathotyping assays (Gimeno et al., 2002).
It is widely understood that highly virulent MDV 
strains replicate earlier, faster and induce higher virae­
mia titres in vivo than strains of lower virulence 
(Rosenberger, 1995). However, there have been only a 
few published studies that clearly document this relation­
ship (see later discussion). Quantitative polymerase 
chain reaction (PCR) assays should be useful to establish 
the amount of viral genomic DNA present after infec­
tion with isolates of differing virulence, but little data 
have yet been published. Thus, viral replication rates and 
viral load can also be considered as another possible 
criterion for pathotyping.
The absence of a universal pathotyping method that 
can be applied in many laboratories around the world is 
a serious limitation to progress on MD research. The 
primary objectives of this review are to discuss the 
concept of pathotypic differentiation of MDV strains 
and to summarize the existing technology applicable to 
the classification of strains according to pathotype. 
Some previously unpublished data relevant to this 
discussion are included. A modified pathotyping assay 
based on comparison of test virus responses with that of 
prototype virus controls is proposed that provides results 
generally consistent with the ADOL method and pre­
sumably could be conducted by reference laboratories. A 
secondary goal is to discuss the merits of different 
response criteria, including immunodepression, clinical 
neurological signs, and virus load as determined by 
quantitative PCR. The intent of this review, therefore, is 
to stimulate movement towards greater uniformity in 
pathotyping technology. With uniform methods, it 
should be easier to compare data between laboratories 
and obtain agreement on pathotypic classification of 
isolates. In turn, this will provide a better basis for the 
identification of biological and molecular properties that 
are relevant to virulence.
Why Pathotyping?
Determination of pathotype is useful for a number of 
reasons. Probably the most frequent application is to 
investigate the cause of excessive MD losses in vacci­
nated flocks. Producers often assume that such losses 
indicate the presence of exceptionally virulent strains, 
although this is not always the case. Control strategies 
for MD are much the same regardless of the pathotype 
of virus present. Another application is the detection of 
new pathotypes, and to document further evolution of 
MD viral strains to greater virulence. If many strains are 
evaluated, information may be obtained on the relative 
proportion of the isolatable virus population represented 
by each pathotype. A battery of properly pathotyped 
virus strains is the starting point for research to associate 
molecular properties of MD viruses with virulence. 
Another important reason is to obtain the most recent 
and most virulent strains to use as challenge viruses to 
test the protective efficacy of vaccines. Thus, pathotyping 
will continue to be a valuable tool in advancing knowl­
edge on MD. An elegant, early example of pathotyping 
as an epidemiological tool is provided by Biggs et al. 
(1972), who found different pathotypes of MD virus 
present in different chickens reared on the same farm.
The Virus Stock is Important!
Viruses to be pathotyped, or to be used as prototype 
controls in pathotyping assays, should meet a number of 
criteria. In all cases, the stock should be free from 
contaminants, have sufficient titre, and be available as a 
collection of similar ampules held as a virus stock (so 
that replicate assays could be conducted). It should not 
be passed excessively in cell culture, as evidence of 
attenuation has been observed between 20 and 30 
passages. A seed stock system is recommended to keep 
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passage levels consistent and low. Most stocks are stored 
as cryopreserved suspensions of infected cells at — 
196°C. Several of these issues are critical and are 
discussed later.
Virus stocks may be prepared as low-passage cell 
culture suspensions or as suspensions of lymphocytes 
from the blood or spleen. Advantages of cell cultures 
include easier titration by plaque assay, ability to 
develop high titre stocks that contain >106 plaque 
forming units (PFUs) per millilitre, and ability to screen 
out chicken anaemia virus (CAV), a common contami­
nant that does not replicate in most avian cell cultures. 
We have found that after six passages in duck embryo 
fibroblasts (DEF), CAV can no longer be detected 
(Witter, unpublished data). Chicken kidney cultures are 
also commonly used for MDV isolation and propagation 
(Churchill & Biggs, 1967; Schat, 2005). Advantages of 
lymphocyte stocks are principally to avoid possible 
attenuation or other mutations that might occur during 
cell culture passage. It is important to keep the type of 
stock consistent in a given experiment; cell culture and 
lymphocyte stocks should not be compared in the same 
set of assays.
Only pure stocks of serotype 1 MDV isolates should 
be pathotyped. Inadvertent contamination of MD viral 
stocks with CAV, reticuloendotheliosis virus, avian 
leukosis virus, or other agents has been common in the 
past and may seriously bias results of pathotyping 
assays. CAV contamination has been mainly a problem 
with lymphocyte stocks (Miles et al., 2001) since the 
virus does not propagate in most cell cultures, but all 
stocks need to be tested, preferably by nested PCR 
assays. Reticuloendotheliosis virus and avian leukosis 
viruses propagate well, without cytopathic effects, in the 
same cultures used for propagation of MDV and are 
detected by the usual assays. Since MD vaccine viruses 
persist for life in vaccinated chickens and commonly are 
present in samples used to isolate field strains (De Laney 
et al., 1995), it is also necessary to insure that the virus 
stock is free from vaccine strains or serotype 2 strains 
present as natural infections in field flocks. This is best 
done by immunofluorescent assays using serotype­
specific monoclonal antibodies (Lee et al., 1983; Cui et 
al., 2004). MD isolates that stain with antibody H19 
(serotype 1) but are negative with antibody Y5 (serotype 
2) or L78 (serotype 3) are assumed to be pure serotype 1. 
However, if the isolate was obtained from chickens 
vaccinated with CVI988 (which is not stained by anti­
body Hl9), one may also stain with antibody T65 that 
detects the CVI988 and GA strains but not other 
serotype 1 viruses (L. F. Lee, personal communication; 
Lee et al., 1983; Cui et al., 2004). Such immunofluor­
escent assays should be applied to cultures that contain 
>100 plaques, since the number of plaques examined 
determines the sensitivity of the test. Cloning or plaque 
purification at the initial isolation step will help reduce 
problems from vaccine strain contamination. Also, 
isolation from chickens with gross tumours usually 
insures a favourable ratio of virulent virus to avirulent 
vaccine strains.
The number of cell culture passages is important. The 
number should be kept low and consistent. At ADOL, 
master seed stocks of field isolates are prepared at DEF 
passage 6. Working stocks are prepared at passage 7 or 
8. Since isolates show little or no change in biological 
properties between passages 6 and 20 (Witter, unpub­
lished data), we assume there is little or no attenuation 
during the initial six to eight passages. However, this is 
impossible to confirm.
Cloning deserves special consideration. A cloned virus 
is by definition derived from a single virus particle. In the 
MD system this is usually achieved by inoculation of cell 
free virus obtained from feather follicles or sonicated cell 
cultures and propagating a virus stock from a single 
plaque. Its purpose is to achieve a uniform virus 
population and to exclude contaminants, important 
attributes of any virus used in research. In practice, 
however, a cloned MD virus may quickly become 
heterogeneous upon cell culture passage. Furthermore, 
a cloned virus may not be as representative of a virus 
population on a farm as an uncloned virus. In contrast, 
plaque purification is usually achieved by inoculation of 
cell associated virus and propagating a virus stock from a 
single plaque. Plaque purification is used to reduce the 
likelihood of contamination with other MD serotypes 
but should not be considered a substitute for cloning. 
Whether to clone or plaque purify is an important 
decision, which is only partly dependent on the require­
ment of pathotyping assays.
A final caution is that the same MD viral strain used 
in different laboratories or prepared at different times 
under different conditions should not be assumed to be 
identical. Isolate 615K was isolated at ADOL from 
material provided by J. Rosenberger identified as strain 
T. King, but it is unlikely that the cell culture propagated 
615K and the T. King isolate propagated in chickens by 
Rosenberger will have identical properties. A preparation 
of strain RB1B, obtained from Cornell University, 
proved to be significantly less virulent after propagation 
at ADOL than its parent strain (Gimeno et al., 1999). 
Unfortunately, this problem is very difficult to identify 
since there is rarely the opportunity for side-by-side 
evaluation of a particular isolate and its original parent 
strain. This issue also exists for viruses cloned from a 
characterized parent strain.
The Chicken is Important Too!
Virulence is defined by the frequency and severity of 
disease induced in a susceptible host chicken. Chickens 
vary greatly in MD susceptibility due to genetics, 
maternal antibodies, and vaccination status. No single 
type of chicken will adequately differentiate all the 
various degrees of virulence represented by different 
MDV isolates. Thus, it is desirable to use multiple groups 
of chickens with graded levels of susceptibility. Highly 
susceptible chickens should differentiate the least viru­
lent strains whereas highly resistant chickens will better 
differentiate strains with higher levels of virulence.
Creation of a suitable series of chicken types with 
differential susceptible to MD is a critical step for 
pathotyping assays. This can probably be done in several 
ways. For the ADOL assay, a highly susceptible chicken 
(cross 15 x 7) derived from vaccinated parents was used. 
Non-vaccinated, HVT-vaccinated, and bivalent (sero­
type 2 + 3)-vaccinated groups were used to provide three 
groups with graded levels of susceptibility. Vaccination 
was considered a better choice than selection of lines 
with different genetic susceptibility because of the 
relevance of vaccines to the practical control of the 
disease. Other genotypes of chickens should also be 
useful, as discussed subsequently. If the chicken strain 
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has moderate levels of genetic resistance, less disease 
may be induced but it still should be possible to 
differentiate pathotypes using non-vaccinated and vacci­
nated groups.
Homogeneity of response is also important. Crosses of 
inbred lines such as 15 x 7 would be expected to yield 
more homogeneous responses than would non-inbred 
stock. It may be useful to consider the genetic diversity, 
especially at the major histocompatibility complex, and 
the degree of inbreeding when selecting a chicken stock 
for pathotyping studies. Freedom from extraneous 
infections is critical. Chicks from specific pathogen free 
(SPF) breeders are desirable, although if MD maternal 
antibodies are desired to decrease MD susceptibility, 
MD-vaccinated SPF breeders may be utilized.
The ADOL Pathotyping Assay (Gold Standard)
Before addressing other options, it may be useful to 
review the current ADOL assay (Witter, 1997) and its 
applications to pathotyping. The data output is based on 
the induction of lymphoproliferative (tumour) lesions. 
The data are compared with that of prototype strains. 
The design tests for the ability of a test virus to break 
through immunity induced by two classes of standard, 
commercial vaccines. Each of these features helps insure 
that the typing is consistent with classified strains and is 
relevant to the process of MDV evolution.
The assay is performed by simultaneous challenge of 
three classes of 15x7 ab + chickens (from dams 
immunized with all three MDV serotypes); unvaccinated, 
HVT-vaccinated and HVT + SB-1-vaccinated. Vaccines 
are administered at hatch at 2000 PFU per chick. 
Challenge is performed at 5 days post vaccination using 
500 PFU per chicken. Two prototype strains, JM/102W 
(v pathotype) and Md5 (vv pathotype), are used as 
controls. Each lot consists of 17 chickens that are housed 
in modified Horsfall-Bauer isolators to prevent inad­
vertent spread of infection between treatment groups. 
The test is terminated and all chickens necropsied at 
about 56 days post challenge. The experiment is fully 
replicated, usually at a subsequent date. Thus, each virus 
is classified on the basis of responses from 102 chickens 
(three treatments x two replications). The gross lesion 
response data of test strains are compared with those of 
control strains using an interaction chi-square analysis 
(Steel & Torrie, 1960). Pathotypes are designated on the 
basis of total lesion responses according to the following:
v Response in HVT-vaccinated chickens does not 
differ from JM/102W.
vv Response in HVT-vaccinated chickens exceeds that 
induced by JM/102W and does not differ from that 
induced by Md5 in HVT/SB-1-vaccinated chickens. 
vv+ Response in HVT/SB-1-vaccinated chickens exceeds 
that induced by Md5.
Another useful parameter, designated as virulence 
rank, can be calculated from the same response data 
(Witter, 1997). The calculation is 100 minus the mean of 
the protective indices obtained in HVT-vaccinated and 
HVT/SB-1-vaccinated chickens. The virulence rank per­
mits a convenient numerical ranking of test isolates from 
0 (very low virulence as indicated by high protection by 
both vaccine types) to 100 (very high virulence as 
indicated by low levels of protection by both vaccine 
types). Since this parameter is based on response data 
from four lots of chickens representing those vaccinated 
with HVT and with HVT/SB-1, respectively, the para­
meter reflects well the ability of a virus to break through 
two different vaccine types.
Although the ADOL assay is generally reproducible, 
there are a number of limitations. The ADOL 15 x 7 
ab + chickens are not readily available for use by other 
laboratories. The power of the statistical assay depends 
on a standard number of chickens and replicates, which 
limits the ability to adjust group sizes and replicate 
numbers. The 9-week holding period results in a very 
high cost for chicken maintenance. Each treatment (three 
chicken types x two replications) requires 102 chickens. 
Thus the number of chickens required to type 2 test 
viruses (using two prototype control strains) is over 400 
chickens. Also, the assay is not designed to differentiate 
m pathotype strains, although it could be adapted to do 
so (see subsequent section).
Reproducibility is relative. We have noted substantial 
variation between replicate trials. For example, virulence 
rank data for the JM/102W and Md5 strains over 10 
replicate trials conducted under nearly identical condi­
tions but at different times were 8.0 to 32.2 (mean 17.6) 
and 39.5 to 69.0 (mean 56.3), respectively (Witter, 
unpublished data). Similar variation among replicate 
control data has been reported earlier (Witter, 1997).
To exemplify the utility and application of the 
procedure, data from ADOL assays on six new field 
isolates are presented in Table 1. In this case, all six 
isolates induced very high rates of MD in non-vacci- 
nated chickens. The incidence of MD in HVT-vaccinated 
chickens varied from 45% to 100%, levels significantly 
greater in all cases than those induced by the JM/102W 
strain. This indicated that the strains were vv pathotype 
or greater. The incidence of MD induction in bivalent- 
vaccinated (HVT + SB-1) chickens varied from 3% to 
58%. The MD frequency of isolate 686 was significantly 
greater than the Md5 strain control, indicating that this 
strain was vv + pathotype. The other five strains did not 
differ from the Md5 control and were thus designated as 
vv pathotype. One should note, however, the variation in 
MD response induced by Md5 in trials 1 and 2, and the 
differences between both of these values and the mean of 
values from 10 previous trials. Depending on which 
value for Md5 was used for comparison, the pathotype 
designations would differ. This illustrates one type of 
problem in the application of the standard ADOL assay.
Modifications of the ADOL Assay
We have investigated two different approaches to im­
prove the standard ADOL assay: (1) inclusion of 
CVI988-vaccinated chickens in the challenge model, 
and (2) use of alternative strains of chickens (and 
different response criteria).
CVI988-vaccinated chickens. Recent studies have ad­
dressed whether the use of CVI98 8-vaccinated 15 x 
7 ab+ chickens would be a useful adjunct to the 
standard ADOL method. Groups of CVI988-vaccinated 
chickens were challenged with a panel of seven vv and 
seven vv + strains, and the results compared with those 
from bivalent-vaccinated (HVT + SB-1) chickens in ear­
lier trials (Table 2). The mean per cent MD lesions and 
the per cent protection between the two groups did not
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Table 1. Pathotyping of six new isolates by the ADOL assay“
Trial Isolate % MD in chickens vaccinated with: Pathotype Virulence rank
None HVT HVT + SB-1
1 670 100.0 45.2* 3.1 VV 24.1
685 100.0 52.9* 6.3 vv 29.6
686 100.0 100.0* 57.6* vv + 78.8
JM/102W 100.0 5.9
Md5 100.0 14.7
2 690 100.0 63.6* 39.4 vv 51.5
691 97.1 52.9* 5.9 vv 30.3
692 100.0 97.1* 50.0 vv 73.5
JM/102W 84.8 19.4
Md5 100.0 44.1
Historic controls JM/102W 92.8 22.3 8.7
Md5 99.8 82.8 28.0
aThe standard ADOL pathotyping assay (Witter, 1997) was applied to the typing of six new field isolates (trials 1 and 2). Line 15x7 
chickens were the Fl progeny of line 15I5 males and line 7i females. The dams received MD vaccine of all three serotypes (Witter, 
1987) so that progeny chicks were considered positive for maternal antibodies (ab + ). Groups of 17 chickens were vaccinated at hatch 
with 2000 PFU of the respective vaccine (none, HVT or HVT + SB-1), challenged with 500 PFU of the respective challenge virus at 5 
days post vaccination, and held in modified Horsfall-Bauer isolators under negative air pressure until the conclusion of the trial, 8 
weeks post challenge. The per cent (%) MD responses are based on the number of dead or killed chickens with gross MD lesions; data 
are pooled from two replicate trials. Virulence rank was calculated as 100 - mean % MD response (HVT and HVT + SB-1 groups). 
The table also includes mean response data from 10 earlier trials (Witter, 1997) for comparative purposes. * Response values greater 
than that for the appropriate control virus response (underlined) in the same column, as determined by interaction chi-square analysis 
(Steel & Torrie, 1960).
differ in CVI988-vaccinated chickens even though robust 
differences were noted in bivalent-vaccinated chickens. 
Thus it does not appear that the use of CVI988- 
vaccinated chickens will assist discrimination between 
the vv and vv+ pathotypes. However, CVI988-vacci- 
nated chickens might be good models to detect new, but 
as yet unrecognized, pathotypes.
To test the possibility that more recently isolated 
MDV strains might have special pathogenicity for 
CVI98 8-vaccinated chickens (as has been anticipated,
Table 2. Challenge of CVI988-vaccinated chickens does not discriminate between vv and vv+ pathotypes“
Isolate Previously published data New data
Pathotype Virulence rank Bivalent (HVT + SB-1) CVI988
% MD % Protection % MD % Protection
679B w 39.4 9.1 91 0.0 61
595 w 61.0 46.7 53 34.0 83
615K w 62.5 35.5 63 17.6 80
677 w 67.8 41.9 58 38.2 57
611 w 70.5 47.1 50 15.2 83
643P w 72.0 44.1 56 26.5 71
Md5 w 57.9 33.1 67 14.7 85
Mean 36.8A 62A 20.9A 74A
645 vv + 79.0 57.6 42 21.2 76
584A vv + 82.5 67.6 32 17.6 80
675A vv + 84.8 69.7 30 21.9 76
652 vv + 86.5 72.7 27 30.3 66
671A vv + 86.8 73.5 26 8.8 90
660A vv + 88.7 64.7 35 23.5 74
648A vv + 91.0 81.8 18 21.2 74
Mean 69.7B 30B 20.7A 77A
aSeven MDV strains of the vv pathotype and seven MDV strains of the vv+ pathotype were evaluated. Previous data on these strains 
obtained with bivalent (HVT + SB-1) vaccinated 15 x 7 ab + chickens are listed (Witter, 1997). New data were obtained for each virus 
by challenge of line 15 x7 ab+ chickens at 5 days post vaccination with 2000 PFU of CVI988 (see Table 1). The CVI988 strain was 
originally obtained from Rhone Merieux through Select Laboratories (Witter et al., 1995). The % MD through 8 weeks post challenge 
was calculated as in Table 1. The % protection is calculated as described in Witter et al. (1995). Groups included 17 chickens. Two 
replicate trials were conducted and the data were pooled. Means in same column identified by different uppercase letters differ (P < 
0.05).
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especially in locations where CVI988 has been used for 
many years, and which was supported by our prelimin­
ary data; Witter, 2001), three vv-l- strains isolated 
between 1990 and 1995 were contrasted with three 
vv + strains isolated between 1997 and 1999 at ADOL. 
In contrast with our preliminary data, the data presented 
in Table 3 show no differences between old and new 
isolates in their relative virulence for CVI988-vaccinated 
chickens. Of course, this does not rule out the possibility 
that such viruses exist or may emerge in the future. 
Continued surveillance is warranted.
We conclude that the inclusion of additional groups of 
CVI988-vaccinated chickens in the standard ADOL 
design is not warranted at this time. Furthermore, 
none of the recent isolates tested appear to exhibit a 
preferential pathogenicity for CVI98 8-vaccinated chick­
ens. Similarly, Buscaglia reported that CVI988-vacci- 
nated chickens were highly resistant to challenge with the 
NULP-1 isolate and yielded no data that would alter 
pathotyping results obtained with other classes of 
vaccinated chickens (Buscaglia et al., 2004).
Alternative chicken strains. Two trials were conducted to 
test whether prototype vv and vv+ isolates could be 
differentiated by biological responses induced in several 
different chicken strains. The first trial compared the 
responses of four chicken strains (7x6 ab —, N ab +, 
TK ab + , and 15 x7 ab —) to challenge at 21 days with 
strains Md5 (vv pathotype) and 648A (vv+ pathotype). 
Five replicate experiments were performed: three with 
non-vaccinated chickens, one with HVT-vaccinated 
chickens and one with HVT + SB-1-vaccinated chickens. 
Mortality and total MD lesion responses were calculated 
through 8 weeks post challenge. Vaccination was at 
hatch (2000 PFU/chick) and challenge was at 21 days of 
age (500 PFU/chicken). The late challenge was designed 
to lessen the effects of maternal antibodies, which were 
present in some chicken lines at hatch but not other lines. 
The data (Table 4) show that TK ab+ chickens 
discriminated between vv and vv-l- isolates when eval­
uated by total MD tumour response, regardless of the 
vaccination status in line TK ab +. However, other lines 
showed only limited differences. Similar results were 
reported by Schat and coworkers who differentiated 
GA5 (v pathotype) and RB1B (vv pathotype) viruses in 
non-vaccinated, genetically resistant N2 chickens but not 
in three other more susceptible strains (Schat et al., 
1981).
The second experiment was to determine whether 
commercial SPF chickens could be substituted for 15 x 
7 ab+ chickens in the standard ADOL assay. Two 
commercial strains, SPAFAS ab — and Hy-Vac line TK 
ab—, were obtained. Six MDV strains representing all 
three pathotypes were used as challenge viruses. The 
protocol followed that of the classical ADOL assay, 
except that only a single non-replicated experiment was
Table 3. Pathogenicity of selected vv+ isolates in chickens vaccinated with bivalent or CVI988 vaccines“
Year isolated Isolate Vaccine n MD + % MD mortality % total MD % protection C/B ratio
1999 686 CVI988 33 10 18.2 30.3 69 >10
HVT + SB-1 34 31 17.6 91.2 6
None 33 33 97 100
1999 690 CVI988 34 4 2.9 11.8 88 1.1
HVT + SB-1 34 8 0 23.5 76
None 34 34 23.5 100
1997 677 CVI988 31 4 6.5 12.9 87 1.6
HVT + SB-1 34 15 0 44.1 54
None 32 31 56.3 96.9
1995 648A CVI988 34 7 17.8 20.6 79 2.5
HVT + SB-1 32 21 3.1 65.6 32
None 33 33 87.9 100
1994 645 CVI988 34 4 0 11.8 88 3.1
HVT + SB-1 33 23 0 69.7 28
None 34 34 0 100
1990 584A CVI988 34 7 2.9 20.6 79 2.0
HVT + SB-1 34 20 9.1 58.8 39
None 34 34 70.6 100
None 10 0 0 0
Summary
1997 to 1999 CVI988 98 18 9.2 18.4 81 1.8
FC126/2 + SB-1 102 54 5.9 52.9 45
None 99 98 58.6 99
1990 to 1995 CVI988 102 18 6.9 17.8 82 2.5
FC126/2 + SB-1 99 64 4 64.6 33
None 101 101 52.5 100
aTo determine whether recent MDV isolates of the vv+ pathotype have increased virulence for CVI988-vaccinated chickens, three 
vv + isolates (1997 to 1999) and three vv+ isolates (1990 to 1995) were used to challenge 15 x7 ab+ chickens that were vaccinated at 
hatch with the respective vaccine (none, CVI988, and HVT + SB-1). Vaccine and challenge doses were 2000 and 500 PFU, respectively. 
MD lesion responses were measured through 8 weeks post challenge. Each treatment group was 17 chickens; two replicate trials were 
conducted and the data were pooled. Data are presented for each virus, and also as pooled data for each group of viruses. The C/B 
ratio, calculated as the % protection by CVI988 divided by the % protection by HVT + SB-1 vaccines, is presented.
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Table 4. Discrimination between vv and vv + isolates by challenge of different lines of chickens at 3 weeks of agea
Trial Vaccine Chicken* 3 Number of chicks % total MD response
648A (vv+) Md5 (vv) 648A (vv+) Md5 (vv)
1 to 3 None 7 x 6 ab — 84 86 93 87
N ab + 79 85 94 84
TKab + 73 73 RÔÔ 53H
15 x 7 ab — 86 85 94 99
4 HVT 7 x 6 ab — 32 32 22 3
N ab + 23 26 22 0
TKab + 24 23 1 67 9 1
15 x 7 ab — 32 32 91 72
5 HVT + SB-1 7 x 6 ab — 28 30 4 0
N ab + 24 18 4 0
TKab + 30 28 1 63 4 1
15 x 7 ab — 29 32 41 6
aFour types of chickens were challenged at 3 weeks of age with 500 PFU vv (Md5) and vv + (648A) pathotypes of MDV. Chickens of 
lines 7 x 6, N and 15x7 were from parents maintained at ADOL; line TK was provided by Hy-Line International. Although lines N 
and TK were derived from parents vaccinated for MD, maternal antibodies were assumed to be largely depleted by the time of 
challenge. Five experiments were conducted: three with non-vaccinated chickens, one with HVT-vaccinated chickens and one with 
HVT +SB-1-vaccinated chickens. Each experiment was conducted as two replicates. Data were pooled for each vaccine type. The % 
MD responses were measured at 8 weeks post challenge and include mortality from early mortality syndrome, transient paralysis and 
MD lymphomas, as well as birds positive for MD lymphomas at the conclusion of the trial. The responses that best discriminate 
between vv and vv+ strains are shaded.
performed with each of the chicken lines. Data 
obtained were compared with those obtained in previous 
trials using the classical ADOL assay in 15 x 7 ab + 
chickens.
Data from SPAFAS chickens are presented in Table 5. 
Although the magnitude of MD responses was lower in 
general compared with 15 x7 ab+ chickens, the pattern 
of responses in SPAFAS chicken followed closely that 
obtained by the classical ADOL assay. Correlations with 
prior data for five response parameters in SPAFAS 
chickens all exceeded 0.8.
Data from Hy-Vac line TK chickens are presented 
in Table 6. Although the susceptibility of this line 
appeared slightly less than that of SPAFAS and con­
siderably less than that of 15 x 7 ab+ chickens, the 
pattern of responses again appeared comparable 
with those obtained by the classical ADOL assay. 
Correlations with prior data for the five response 
categories was generally good (except for virulence 
rank), but were not as good as those obtained with 
SPAFAS chickens.
These results suggest that MDV pathotypes may be 
successfully differentiated in chickens of alternative 
genotypes. Buscaglia was able to type viruses successfully 
using P2a and N2a chickens (Buscaglia et al., 2004). 
However, Burgess correctly points out that host genetic 
background can be important when pathotyping MD 
viral isolates (Burgess et al., 2001)
Table 5. Pathotyping data in SPAFAS ab- chickens using standard ADOL assay protocol: correlations and best fit pathotypea
Virus 15 x7b % MD % mortality
Pathotype Virulence rank HVT vaccinated Bivalent vaccinated Not vaccinated Not vaccinated Virulence rank Best fit
JM/102W V 17 17.6 5.9 76.5 29.4 15
Md5 w 56 23.5 18.8 88.2 70.6 24
648A vv + 84 35.3 41.2 100.0 100.0 38
571A V 19 5.9 7.7 81.3 18.8 8 Ve
549A w 54 47.1 23.5 94.1 94.1 35 vv+d
660A vv + 89 64.7 47.1 100.0 100.0 56 vv+e
Correlation coefficientf 0.82 0.98 0.90 0.94 0.92
aChickens obtained from SPAFAS, Inc. were utilized in the ADOL pathotyping assay (see Table 1) with the following modifications. 
The chickens were from non-vaccinated parents (ab-). Three prototype control strains were used: JM/102W, Md5 and 648A 
representing the v, vv and vv+ pathotypes, respectively. Only one replicate trial was conducted and each group contained about 17 
chickens which were vaccinated at hatch, challenged at 6 days post vaccination and terminated 8 weeks post challenge. Bivalent 
vaccine, HVT + SB-1.
bData from earlier trials with replicate lots of 17 chickens per treatment.
cGood fit with JM/102W by all criteria.
dFits between Md5 and 648A by most criteria, assigned vv+ on basis of HVT and virulence rank.
cGood fit with 648A by all criteria, exceeds 648A by some criteria. 
fCompared against virulence rank value determined in 15 x 7 chickens by an excel program.
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Table 6. Pathotyping data in Hy-Vac line TK ab- chickens using standard ADOL assay protocol: correlations and best fit pathotypea
Virus 15 x7b % MD % mortality
Pathotype Virulence rank HVT vaccinated Bivalent vaccinated Not vaccinated Not vaccinated Virulence rank Best fit
JM/102W V 17 5.9 0.0 41.2 11.8 7
Md5 vv 56 11.8 11.8 88.2 41.2 13
648A vv + 84 50.0 18.8 100.0 94.1 34
571A V 19 29.4 26.7 47.1 23.5 68 Ve
549A vv 54 11.8 11.8 100.0 100.0 13 vvd
660A vv + 89 35.3 31.3 100.0 94.1 33 vv + e
Correlation coefficient 0.62 0.48 0.91 0.86 -0.09
a Chickens of Hy-Vac line TK ab — were utilized in a pathotyping assay as described for Table 5. Data are based on single lots of 17 
chickens vaccinated at hatch, challenged at 6 days post vaccination and terminated 8 weeks post challenge. Bivalent vaccine, HVT + 
SB-1.
bData from earlier trials with replicate lots of 17 chickens per treatment.
cGood fit with JM/102W in not vac chickens, but exceeds JM/102W by other criteria.
dGood fit with Md5 by most criteria, but % mortality most closely resembles that of 648A. 
cGood fit with 648A by most criteria.
fCompared against virulence rank value determined in 15 x 7 chickens by an excel program.
The “Best Fit” Concept
Given that several different lines of chickens appear 
useful in differentiation of pathotypes, a need exists for 
standardization of responses to account for susceptibil­
ity differences between chicken lines. An obvious 
approach is to compare responses with those of proto­
type challenge viruses representing the three pathotypes. 
The appropriate pathotype would be assigned based on 
the prototype virus response that best matches that of 
the test virus. This process of “best fit” can be done 
statistically, but should also be possible by visual 
inspection of the data. This concept is illustrated with 
data from the trial already presented (Tables 5 and 6).
In each set of data, one should first study the 
responses of the three prototype control strains, in this 
case JM/102W (v), Md5 (vv) and 648A (w+). Strain 
571A appears by visual comparison to match best with 
JM/102W in both datasets, especially when one con­
siders data obtained in non-vaccinated chickens; this 
strain can thus be designated as pathotype v. Strain 
549A is a bit more problematic. In SPAFAS chickens, 
this strain fits between Md5 and 648A by most criteria, 
but was designated as vv+ based on responses in HVT- 
vaccinated chickens and by the virulence rank para­
meter. In Hy-Vac line TK chickens, this strain fits best 
with Md5 by most criteria and, even though mortality in 
non-vaccinated chickens was closer to that of 648A, it 
was designated as vv pathotype. Strain 660A data was an 
excellent fit with that of 648A in both types of chickens 
and was designated as vv+ pathotype. This illustrates 
the application of the “best fit” method. Strains 571A 
and 660A were properly classified in both lines of 
chickens. Strain 549A was properly classified in Hy-Vac 
line TK chickens, but not in SPAFAS chickens. This 
strain is probably intermediate in pathogenicity between 
vv and vv+ prototype strains and, thus, may be more 
difficult to classify.
This suggests that a visual best fit method using 
commercially available SPF chickens could yield similar 
pathotype rankings as the standard ADOL method. 
Additional modifications to reduce the numbers of 
chicken required are illustrated (Table 7). Instead of 
conducting a complete, balanced experiment in two 
replicates, one could first screen isolates in non-vacci­
nated chickens (Qualitative test A) to determine patho­
genicity relative to a prototype v pathotype strain. 
Viruses that closely resemble the v prototype could be 
classified without further study. This assay would also 
identify and properly classify avirulent strains. Only 
those isolates that are clearly more virulent than the v 
prototype would be tested in a second screen in two 
types of vaccinated chickens (Quantitative test B). The 
total number of chickens required could be less than with 
the balanced experiment. Furthermore, one could elect 
to conduct only a single replicate, although we have 
learned that the precision of the standard ADOL test is 
improved through replication.
Alternative Criteria
The best fit method using commercial SPF or other 
chickens is also adaptable, in principle, for use with 
alternative response criteria. The principle of compar­
ison of responses with those induced by prototype virus 
strains is independent of the specific criterion used. This 
concept adds important flexibility to the assay, although 
one should be cautious when substituting alternative 
response criteria where the correlation with pathotype is 
not well documented. Several such alternative criteria 
are now discussed.
Immunodepression. Calnek et al. (1998) reported a strong 
relationship between pathotype and persistence of early 
cytolytic infection, viraemia titres, and relative lymphoid 
organ weights. It appeared that, compared with low 
virulence strains, viruses of greater virulence caused 
more persistent and higher titre infections, and induced 
greater atrophy of the bursa of Fabricius and thymus. 
These effects were apparent as early as 8 to 10 days post 
inoculation in both P2a and N2a chickens. The authors 
suggested use of organ weight as a suitable criterion to 
determine the pathotype.
Collaborative work was undertaken to extend these 
findings. In the first set of experiments, a battery of 19 
selected ADOL virus strains representing all three 
pathotypes were provided for challenge in P2a and 
15 x 7 ab — chickens at Cornell University (Table 8).
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Table 7. Two-step experimental design for pathotyping by best fit method
Test Lot Chicks Chicken strain Vaccine 2000 PFU Virus challenge Test duration
Strain PFU Age
Aa 1 10 SPF, ab - None Virus Ie 500 1 day 56 ped
2 10 JM/102W 500 1 day
3 10 Md5 500 1 day
4 10 None 500 1 day
Bb 1 14 SPF, ab - HVT Virus Ie 500 5 pvd 56 ped
2 14 JM/102W 500 5 pvd
3 14 Md5 500 5 pvd
4 14 648A 500 5 pvd
5 14 None 500 5 pvd
6 14 HVT + S2 Virus Ie 500 5 pvd
7 14 JM/102W 500 5 pvd
8 14 Md5 500 5 pvd
9 14 648A 500 5 pvd
10 14 None 500 5 pvd
aTest method A: compare mortality and tumour response to controls. Viruses that resemble JM/102W more closely than Md5 are 
designated as pathotype v. Viruses that induce no response are classified as nonpathogenic. Other viruses are tested further (Test B). 
pvd, post vaccination day; ped, post challenge day.
bTest method B (viruses with greater virulence than JM): compare mortality and tumour resonse to controls. Consider data from both 
vaccinated lots. Strains that best resemble JM/102W are classified as pathotype v. Strains that best resemble Md5 are classified as 
pathotype vv. Strains that best resemble 648A are classified as pathotype vv +. For strains with measurable virulence but less than that 
of JM, revise design to include JM/102W and CU-2 as prototype controls (omitting Md5 and 648A).
^Additional viruses are tested by inserting additional treatment groups.
Although there was a slight but consistent tendency for v 
pathotype strains to induce less organ atrophy than 
other pathotypes at 8 days post inoculation, significant 
differences in mean bursa and thymus weights were not 
observed between viruses of the different pathotype 
groups in either type of chicken. Relative organ weight
Table 8. Lymphoid organ weights in chickens inoculated with serotype 1 MDVsa
Pathotype Strain 15x7 (ab—) P2a (ab — )
Number of trials Bursa weight Thymus weight Number of trials Bursa weight Thymus weight
V JM/102W 3 74.0 62.7 5 71.8 47.6
571A 2 67.0 62.5 3 74.0 60.3
596A 2 63.0 59.0 3 76.3 59.7
617A 2 56.5 61.5 1 108.0 80.0
vv Md5 3 66.0 61.7 5 65.0 53.4
RB1B 0 1 62.0 43.0
549A 2 57.0 58.5 3 68.3 53.7
587A 2 60.5 59.5 3 67.3 70.3
595 0 2 52.5 35.0
643P 0 2 66.0 61.5
653A 2 47.5 41.5 1 75.0 51.0
vv + 584A 0 2 66.0 51.5
610A 2 57.5 63.5 1 88.0 66.0
645 2 49.0 44.5 3 74.3 50.3
648A 0 2 64.5 46.0
648B 2 55.5 57.5 1 70.0 55.0
651 0 2 68.0 59.5
660A 0 2 57.0 46.0
776 0 2 67.0 65.5
Group means
V 4 4 65.1 A 61.4A 4 82.5A 61.9A
vv 7 4 57.8 A 55.3A 7 65.2A 52.6A
vv + 8 3 54.0A 55.2A 8 69.4A 55.0A
aTrials were conducted at Cornell University using previously described techniques (Calnek et al., 1998). Chickens were inoculated at 
14 days of age with about 500 PFU of virus. Organs were harvested 8 days post inoculation, weighed and converted to relative weights. 
Data are expressed as the percent of control relative weights. Six trials were conducted; three with P2a ab — chickens, one with 15x7 
ab — chickens, and two with both chicken types. Not all viruses were tested in each trial (see table for number). The number of 
chickens per treatment group varied from three to eight (trials 1 and 2) and from nine to 10 (trials 3 to 6). The RB1B stock was from 
Cornell. All other stocks were supplied by ADOL. Means followed by different uppercase letters within the same column re different 
(P <0.05) by Bonferroni t test (Games, 1977).
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values for vv and vv+ pathotype strains were virtually 
identical.
A second collaborative experiment was conducted at 
ADOL to evaluate the variability of MDV isolates for 
immunodepressive properties, to determine the relation 
between immunodepression and pathotype, and to 
determine the effect of HVT vaccination on immunode­
pression. Eight selected MDV strains representing all 
three pathotypes were used to challenge non-vaccinated 
and HVT-vaccinated chickens of lines 15 x 7 and TK.
Data presented in Table 9 show that, in non-vacci­
nated chickens, viruses of all pathotypes induced marked 
depression of relative lymphoid organ weights at 8 days 
post challenge; mean weights of bursa and thymus in 
both strains of chickens varied from 48% to 60% of 
control values (see non-vaccinated mean). However, 
correlations with virulence rank data obtained in prior 
assays were poor. HVT vaccination appeared to com­
pletely abrogate the atrophic effects of MDV challenge 
on the bursa and greatly reduced the atrophic effects on 
the thymus. Correlations with virulence rank data were 
poor. These data do not support the thesis that organ 
weights will discriminate between MDV pathotypes on a 
consistent basis.
Reproducibility of organ weight data can be examined 
for four virus strains (571 A, 596A, 610A and 648B) 
tested in 15x7 ab — chickens in the two sets of trials 
(Tables 8 and 9). Agreement was not particularly good as 
one of four bursal weights and three of four thymus 
weights were markedly lower in the second trial (Table 9) 
compared with the first trial (Table 8). Another problem 
was the identification of what appeared to be improperly 
inoculated chickens in the second trial. Sporadically, in 
non-vaccinated groups challenged with MDV strains, a 
chicken would have lymphoid organ weights identical to 
that of the control whereas all other chickens would have 
markedly depressed organ weights. As this phenomenon 
seemed to be correlated with the inoculation technique, 
non-responder chickens were excluded from the data 
summary (Table 9). Problems such as these would need 
to be resolved before lymphoid organ weight parameters 
could be used with confidence.
Since the immunodepressive potential of MDV strains 
as estimated from relative organ weights was limited or 
absent in HVT-vaccinated chickens, immunodepressive 
properties may not greatly influence pathotyping assays 
if the assays are conducted in chickens immunized with 
HVT or other MD vaccines. The possibility that 
pathotyping data obtained from non-vaccinated chick­
ens might not correlate well with that obtained from 
vaccinated chickens, because immunodepressive factors 
may be more important in the former compared with the 
latter, is an intriguing issue but has not been yet 
investigated.
In summary, it appears that a relationship between 
relative bursa and thymus weights and virulence as 
previously reported (Calnek et al., 1998) is not consis­
tently expressed with all virus strains. Thus, the value of 
this criterion for pathotyping is uncertain at best, and 
deserves additional validation prior to use.
Neuropathotyping. Gimeno et al. (2002) reported on a 
statistical approach to the analysis of clinical neurologi­
cal responses to 29 different MDV strains of known 
pathotype. Three clusters (groups) were derived and were 
designated A, B and C according to ascending grades of 
neurological response. There was a clear relation be­
tween neuropathotype and pathotype. For example, 
neuropathotype A contained the JM/102W strain (pro­
totype v pathotype), neuropathotype B contained the 
Md5 strain (prototype vv pathotype) and neuropatho­
type C contained the 648A strain (prototype vv + 
pathotype). However, neuropathotype C included most 
of the vv pathotype strains in addition to all vv + 
pathotype strains. Table 10 illustrates the relation 
between pathotype and neuropathotype. There is a very 
good fit between pathotype v and neuropathotype A, 
and between pathotype vv-l- and neuropathotype C. 
Pathotype vv, however, includes all three neuropatho- 
types, although most are concentrated in either 
neuropathotype B or C. The authors suggest neuro­
pathotyping as an adjunct rather than a replacement for 
traditional pathotyping (Gimeno et al., 2002).
Neuropathotyping was also conducted successfully in 
SPAFAS and Hy-Vac line SC chickens, indicating again 
that pathotypic differences can be measured in chickens 
of various, but not all, genotypes (Gimeno et al., 2002). 
Even though the statistical method for assignment of 
neuropathotype groups did not fit the existing pathotype 
classification, the correlation between neurological clin­
ical signs and virulence was strong. Neurological re­
sponses induced by each of the three prototype viruses 
were well differentiated from each other. Thus, neurolo­
gical responses should be useful for pathotyping when 
compared with prototype strains by the best fit method.
Virus replication and virus load. Some workers have 
noted that isolates of higher virulence, especially W + 
strains, tend to grow faster and produce higher virus 
titres in inoculated chickens compared with isolates of 
lower virulence (Rosenberger, 1995). Calnek and cow­
orkers noted such a relationship between pathotype and 
the number of virus plaques induced in cell cultures 
inoculated with splenocytes obtained 4 to 8 days post 
inoculation (Table 11). Others have observed similar 
trends with samples collected at various time periods. 
However, plaque assays in cell culture to detect cell- 
associated infectivity yield highly variable data, making 
it difficult to detect small differences between groups of 
samples. Quantitative PCR assays to detect viral DNA 
offer a more sensitive approach to the determination of 
virus load in various tissues (Bumstead et al., 1997; 
Burgess & Davison, 1999; Reddy et al., 2000). Yunis et 
al. (2004) have used a real-time reverse transcriptase- 
PCR assay to detect viral transcripts against gB and 
ICP4/LAT produced during 1 to 10 days post infection 
(d.p.i.). The data differentiated the prelytic period (d.p.i. 
1 to 3) when transcripts were barely detectable, the lytic 
phase (d.p.i. 4 to 5) when both transcripts were clearly 
detectable in JM-16, and the latent phase (d.p.i. 6 to 10) 
when transcript levels were low in JM-16-infected 
chickens. Comparisons between the JM-16 strain (v 
pathotype) and RK-1 (vv-l- pathotype) clearly illustrate 
the greater in vivo replication potential for vv+ isolates 
during the lytic and latent phases of infection (Table 11). 
Although the relationship between virus replication or 
virus load and pathotype has not been rigorously tested, 
it appears that these parameters are correlated and that 
values for prototype strains may differ. Thus, the use of 
virus load as a response criterion for comparison with 
prototype strains in a best fit assay could be considered. 




Table 9. Relationship between virulence and lymphoid organ weight depression“
Virus Pathotype Virulence rank Bursa weights (% of control) Thymus weights (% of control) Non-vaccinated mean
Non-vaccinated HVT vaccinated Non-vaccinated HVT vaccinated
15 x7 TK 15 x7 TK 15 x7 TK 15 x7 TK
571A V 19.5 67.6 80.7 95.2 95.3 46.6 39.2 73.6 83.0 58.5
596A V 28.5 39.5 83.5 93.1 99.2 34.9 50.2 75.5 83.6 52.0
653A vv 42.5 49.5 60.2 90.9 106.1 26.8 57.8 69.2 118.2 48.6
595 vv 61.0 50.2 76.9 101.0 120.1 44.1 36.6 78.2 86.9 52.0
610A vv + 79.5 56.1 52.6 85.5 113.7 30.5 76.1 72.3 107.8 53.8
676 vv + 85.0 44.1 75.9 99.5 110.6 39.7 69.9 85.2 67.4 57.4
648B vv + 87.0 57.7 63.9 81.4 113.6 54.6 64.3 75.6 65.9 60.1
660A vv + 89.0 50.3 59.6 95.2 122.0 34.0 57.5 76.4 107.4 50.4
Correlation coefficient13 -0.12 -0.59 -0.21 0.84 0.09 0.66 0.43 -0.10 0.14
aEight MDV strains, representing all three pathotypes and selected to include viruses that appeared to differ for immunodepressive properties, were used. Groups of chickens of line 15 x 7 ab — and Hy-Vac 
line TK ab — that differed in MD susceptibility were either vaccinated at hatch with 2000 PFU of HVT or were left unvaccinated. All chickens were challenged at 7 days post vaccination with 500 PFU of 
the respective MDV strain. Non-challenged control lots for each vaccine and chicken type were also used. Chickens were killed 8 days post challenge. Body weight, relative bursa weight and relative thymus 
weight were determined for each chicken as described (Witter et al., 1997). The trials were conducted in four replicates; two replicates with 15 x7 ab — chickens and two replicates with TK ab — chickens. 
Each treatment group contained about eight chickens. Weights are expressed as a per cent of control weight. The non-vaccinated mean is the mean of all non-vaccinated values, including both organs and 
both chicken strains. A small proportion of non-vaccinated, MDV-challenged chickens had normal organ weights and differed from other treated chickens in the same group. These were considered to be 
non-responders due to errors in inoculation and the data were excluded.
bCompared with virulence rank values (determined from earlier trials).
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Table 10. Relation between pathotype and neuropathotypea
Pathotype Number of strains Number of strains classed as neuropathotypeb
A B C
V 6 5 1 0
vv 13 1 4 8
vv + 10 0 0 10
aData from Gimeno et al. (2002).
bNeuropathotype classification: A, variable classical transient paralysis (TP), low TP with mortality before 15 days (acute TP), low 
persistent neurological disease (neurological signs starting at 19 days or later) (PND); B, hi TP, low acute TP, high PND; C, high TP, 
high acute TP, high PND.
differences in viral titres between pathotypes are more 
evident at later ages, probably reflecting the generation 
of tumour cells, than during the initial cytolytic phase 
(Schat et al., 1982).
controls would be indicated (see Table 7). Alternatively, 
inoculation of 8-day embryos may provide a more 
susceptible host system for evaluation of low virulence 
strains (Calnek et al., 1977).
Pathotyping Mild Strains
A pathotypic classification of mildly virulent (m) was 
proposed (Witter, 1997) to include serotype 1 strains 
such as CU2 (Smith & Calnek, 1974), B14 (Biggs & 
Payne, 1963) or other classical isolates (Biggs & Payne, 
1967; Biggs & Milne, 1972). Such strains are less virulent 
than viruses of the v pathotype such as the JM, GA and 
HPRS-16 strains. The ADOL method is not appropriate 
for such strains without modification; namely, the 
inclusion of a control virus representative of the m 
pathotype. At present, low virulence viruses are rarely, if 
ever, isolated from field cases. It is important to 
differentiate low virulence strains from apathogenic 
strains of serotype 2. However, if a strain appears 
much less virulent than JM and contains serotype 1 
antigens, a follow-up test in non-vaccinated, MD- 
susceptible chickens using prototype v and m strains as
Prototype Strains
The best fit method requires that data be compared with 
those of prototype strains. However, the use of prototype 
strains can also provide a powerful and simple method 
to standardize results in different laboratories, providing 
that the same set of strains is utilized. We suggest three 
prototype strains for consideration: JM/102W (v patho­
type), Md5 (vv pathotype) and 648A (vv+ pathotype). 
The JM/102W and Md5 strains are currently on deposit 
with the American Type Culture Collection (ATCC), 
Rockville, Maryland, USA. The 648A strain has been 
accepted for deposit by the ATCC. These strains may 
also be obtained from ADOL. Characteristics of these 
strains are described in Table 12. It is important, of 
course, that these strains be kept at very low cell culture 
passage to avoid modification of virulence through 
attenuation. Other strains could also be used as controls,
Table 11. Relationship between pathotype and virus load
Trial Virus strain Pathotype Chicken strain Days post challenge PFU/106 leukocytes Real-time reverse transcriptase PCRz
ICP4/LAT gB
Aa JM-16 V P2a 4 to 8 14.4+2.7
RB1B w P2a 4 to 8 41.2+5.5
RK1 w + P2a 4 to 8 30.3+7.3
Bb JM-16 V N2a 1 to 3 0.017 0.045
RK-1 w + N2a 1 to 3 0.008 0.012
JM-16 V N2a 4 to 5 0.483 0.577
RK-1 w + N2a 4 to 5 0.736* 0.752
JM-16 V N2a 6 to 10 0.039 0.196
RK-1 w + N2a 6 to 10 0.316* 0.509*
Cc R2/13 Virulent 15 x 7 ab — 14 137
R2/22 Virulent 15 x 7 ab — 14 127
R2/23 Avirulent 15 x 7 ab — 14 19
R2/29 Avirulent 15 x 7 ab — 14 31
aData from Calnek et al. (1998). Data are pooled from 30 birds/group over 4 to 8 days post inoculation. Leukocytes were obtained 
from spleens.
bData from Schat and coworkers (Yunis et al., 2004). RNAwas harvested from spleens between 1 and 10 days post infection (d.p.i.) 
and the levels of ICP4/LAT and gB transcripts were measured by real-time reverse transcriptse-PCR. Data are the mean number of 
ICP4/LAT and gB transcripts during the prelytic (1 to 3 d.p.i.), lytic (4 to 5 d.p.i.) and latent (6 to 10 d.p.i.) period. The values were 
normalized for cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript copies. * Significantly different at P < 0.05 
between JM-16 and RK-1 for the same period post infection.
cData from Witter (1991). Data are from four clones of Mdll/75C/R2 that vary in virulence. Leukocytes were obtained from buffy 
coat preparations.
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Table 12. Suggested serotype 1 prototype strains for best fit pathotyping
Strain Pathotype Virulence rank Clone Passage ATCC number Neuropathotype Reference
JM/102W V 17.8 Yes 11 to 13 DEF VR-585 A Sevoian et al. (1962),
Stephens et al. (1976)
Md5 w 55.7 No 5 to 7 DEF VR-987 B Witter et al. (1980)
648A w + 80.9 No 6 to 8 DEF VR-1576 C Witter (1997)
providing they are first rigorously compared with the 
aforementioned prototype strains and established to be 
representative of the respective pathotypic group. How­
ever, there is a caveat to this approach. Since virulence of 
MDVs represents a continuum, no two viruses will 
probably be identical. Thus an alternative control virus 
will probably represent a different spot in this continuum 
and inevitably bias the result. For this reason, use of 
alternative strains should be reserved for situations 
where standard prototypes cannot be obtained.
In principle, prototype strains always should be 
cloned. However, the fact that Md5 and 648A are not 
cloned should not affect their suitability as controls for 
pathotyping assays. If these viruses are cloned in the 
future, it would be important to compare the patho­
genicity of the clones with the parent strains.
Conclusions and Recommendations
A modification of the standard ADOL assay based on 
the use of commercial SPF (or other) chickens should be 
adaptable to many laboratories. Furthermore, the pro­
cedure can be enhanced when responses are compared 
with those of prototype control strains by a best fit 
method. Measurement of 8-week tumour responses 
should ensure that the data will be relevant to published 
pathotypes. Widespread use of this method should 
provide greater standardization of pathotype data gen­
erated by different laboratories. This approach has not 
yet been validated. However, this method is currently 
being evaluated in Russia and the initial results appear 
promising (E. Dudnikova, personal communication, 
2004).
Although the ability to utilize commercial SPF chick­
ens removes an important obstacle to international use 
of a standard pathotyping assay, other obstacles may be 
encountered. Some countries, such as Australia and the 
United States, have regulations that severely restrict 
importation of viruses. If prototype strains cannot be 
imported, the modified assay described here cannot be 
conducted. One solution would be for tests to be 
conducted in a third country that has access to the 
ADOL prototype strains and a liberal policy for 
receiving field isolates from foreign countries. Once local 
MD viral isolates have been stringently compared with 
the prototype strains, then one or more local isolates 
could be used to control pathotyping tests in the country 
of origin.
There is a need for more work on alternative criteria 
for pathotyping, especially viral replication and viral 
load (in vivo). Although organ weights and neurological 
signs appear to have limited applicability, parameters of 
viral replication have not yet been sufficiently investi­
gated as a differentiation tool. These criteria are 
attractive because data can be obtained in a much 
shorter time using fewer chickens that do not develop 
tumours, factors that would facilitate approval of pro­
tocols by Institutional Animal Care and Use Commit­
tees.
Finally, it is important to consider whether, in the 
course of future studies, specific molecular changes in 
the viral genome will be identified that will offer 
definitive and rapid means for pathotyping. Thus far, 
there is no indication that virulence of MDV has a 
simple genetic basis. Comparisons of virulent and 
attenuated strains have revealed many differences. Ex­
pansions of a 132 base pair repeat have been associated 
with attenuation (Fukuchi et al., 1985; Silva & Witter, 
1985), but this is now known to be unrelated to virulence 
(Silva et al., 2004). Mutations in the meq gene have been 
associated with variations in virulence (Chang et al., 
2002) but there are insufficient data to justify use of such 
criteria for pathotyping. This issue awaits the dissection 
of the molecular basis of viral virulence—a critical and 
complex issue that will remain a high priority in MD 
research for the foreseeable future.
Validation of alternative criteria should be based on 
tests with multiple representative strains of each patho- 
type. The ADOL virus collection, which contains 47 
strains of serotype 1 MDV pathotyped by the original 
ADOL assay, could be useful in such studies.
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Le concept de pathotype pour la maladie de Marek (MD) date probablement de l’identification d’une forme 
plus virulente de la maladie à la fin des années 1950 (Benton & Cover, 1957). Les distinctions entre les 
souches de virus de la MD (MDV) ont été développées plus tardivement avec la description des pathotypes 
très virulents (vv) au début des années 1980 et des hypervirulents (vv+) dans les années 1990. Les 
désignations de pathotype reflètent des propriétés biologiques importantes qui correspondent au 
franchissement de l’immunité vaccinale sur le terrain. Cependant les méthodes de pathotypage, mises en 
pratique dans différents laboratoires, n’ont pas été les mêmes empêchant la comparaison critique des 
résultats. Une meilleure harmonisation des procédures de pathotypage est souhaitable.
La méthode du Laboratoire des Maladies Aviaires et d’Oncologie (ADOL) est basée sur l’induction des 
lésions lymphoprolifératives chez les poulets vaccinés. Cette méthode a été utilisée pour pathotyper plus de 
45 souches et est la base de la classification actuelle par pathotype des souches de MDV. Les limites de cette 
méthode incluent les exigences en ce qui concerne le type de poulets (15x7 ab+), un nombre important 
d’animaux, et une méthode statistique pour comparer les réponses lésionnelles à celles des souches témoins 
JM/102W et Md5. Du fait de ces limites, cette méthode n’a pas été utilisée dans d’autres laboratoires, et ne 
sera probablement pas.
La comparabilité du pathotypage peut être améliorée par la comparaison des souches du terrain à des 
souches prototype standard, telles la JM/102W, la Md5 et la 648A (American Type Culture Collection) ou à 
des souches équivalentes. Les données peuvent être générées par différentes procédures in vivo qui mesurent 
l’induction des tumeurs, la maladie neurologique (les lésions néoplastiques et non-néoplastiques), ou 
seulement les critères non-néoplastiques (tel les poids des organes lymphoïdes ou la réplication virale). Les 
méthodes basées sur les critères néoplastiques, particulièrement quand ils apparaissent chez des poulets 
immunisés MD, devraient probablement correspondre plus étroitement à celles de la méthode d’ADOL et 
être plus en rapport avec l’évolution des virus sur le terrain. A partir des données de plusieurs essais, une 
modification de la méthode de l’ADOL est proposée. Elle utilise moins de poulets et peut être réalisée avec 
des variétés commerciales de poulets SPF. Cette méthode modifiée est basée sur de meilleures comparaisons 
des souches prototypes, et on peut s’attendre à fournir des résultats généralement comparables à ceux de la 
méthode originale. D’autres critères alternatifs (Cf.supra) sont également évalués aussi bien pour le premier 
pathotypage que comme compléments à d’autres méthodes de pathotypage. Les avantages et les 
inconvénients de ces méthodes alternatives sont présentés.
Der Begriff des Pathotyps bei der Marekschen Krankheit (MK) entstand wahrscheinlich im Zusammenhang 
mit dem Auftreten einer virulenteren Form der Erkrankung in den späten 1950iger Jahren (Benton &Cover, 
1957). Die Unterscheidung zwischen verschiedenen MK-Virus (MKV)-Stämmen wurde mit der Beschrei­
bung des vv-Pathotyps in den frühen 1980iger Jahren und des vv +-Pathotyps in den 1990iger Jahren weiter 
ausgedehnt. Diese Pathotypbezeichnungen reflektieren wichtige biologische Eigenschaften, die mit 
Impfdurchbrüchen im Feld im Zusammenhang stehen. Die Pathotypisierungsmethoden in verschiedenen 
Laboratorien waren jedoch nicht einheitlich, was einen tatsächlichen Vergleich der Ergebnisse bislang 
verhinderte. Aus diesem Grund ist die Vereinheitlichung der Pathotypisierungsverfahren wünschenwert.
Die Methode des ,Laboratoriums für Vogelkrankheiten und -onkologie‘ (Avian Disease and Oncology 
Laboratory (ADOL)) basiert auf der Induktion lymphoproliferativer Läsionen in vakzinierten Hühnern.. 
Diese Methode wurde für die Pathotypisierung von mehr als 45 Isolaten verwendet und ist die Basis für die 
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derzeitige Pathotyp-Klassifizierung von MKV-Stämmen. Ihre Anwendung ist eingeschränkt aufgrund des 
Erfordernis eines bestimmten Hühnertyps (15x7 ab+), einer großen Anzahl von Versuchstieren und einer 
statistischen Methode, die den Vergleich der auftretenden Läsionen mit denjenigen durch die Kontroll­
stämme JM/102W und Md5 ermöglicht. Aufgrund dieser Einschränkungen war und ist diese Methode nicht 
für die Anwendung in anderen Laboratorien geeignet.
Die Vergleichbarkeit der Pathotypisierung kann durch den Vergleich von Feldisolaten mit Standardproto­
typstämmen wie JM/102W, Md5 und 648A (American Type Culture Collection) oder ihrer Äqivalente 
verbessert werden. Die entsprechenden Daten können durch zwei verschiedene in vivo -Verfahren gewonnen 
werden, die entweder die Tumorinduktion und die neurologische Erkrankung (sowohl neoplastische als auch 
nicht-neoplastische Veränderungen) oder nur nicht-neoplastische Kriterien (wie Gewicht der lymphatischen 
Organe oder Virusreplikation) ermitteln. Ergebnisse, die auf der Bestimmung neoplastischer Kriterien 
basieren, insbesondere wenn sie in MK-immunisierten Hühnern durchgeführt werden, werden wahrschein­
lich am ehesten mit den nach der ADOL-Methode erhobenen Daten korrelieren und für die Beurteilung der 
Evolution des MKV im Feld von größter Bedeutung sein. Basierend auf den Daten von verschiedenen 
Untersuchungen wird eine Modifizierung der ADOL-Methode, bei der weniger Hühner verwendet werden, 
die außerdem aus kommerziellen SPF-Stämmen sein können, vorgeschlagen. Die modifizierte Methode 
basiert auf »Best Fit“-Vergleichen mit den Prototypstämmen, d.h. mit welchem Prototyp gibt es die größte 
Übereinstimmung in den Befunden, und es wird erwartet, dass sie Ergebnisse erbringt, die mit denen der 
Originalmethode generell vergleichbar sind. Eine Vielzahl von anderen Alternativkriterien (siehe oben) 
wurden ebenfalls auf ihre Eignung sowohl für die Primärpathotypisierung als auch als Ergänzung zu 
anderen Pathotypisierungsmethoden beurteilt. Vor- und Nachteile dieser Alternativmethoden werden 
erläutert.
El concepto de patotipo en la enfermedad de Marek (MD) data probablemente de finales de los 1950s 
cuando se reconoció una forma más virulenta de enfermedad (Benton y Cover, 1957). Las distinciones entre 
las diferentes cepas de virus de MD (MDV) fueron aún mayores al describirse el patotipo vv a principios de 
los ochenta y el vv+ en los noventa. La designación de patotipo refleja propiedades biológicas importantes 
que se correlacionan con la capacidad de romper la inmunidad maternal en el campo. A pesar de ello, los 
métodos de clasificación de los diferentes patotipos en varios laboratorios no han sido uniformes, lo cual ha 
impedido una comparación crítica de los resultados.
El método utilizado en el Avian Disease and Oncology Laboratory (ADOL) se basa en la inducción de 
lesiones linfoproliferativas en pollos vacunados. Este método ha sido utilizado para clasificar más de 45 
aislados y es la base para la clasificación actual de los patotipos de cepas de MDV. Las limitaciones de este 
método son varias: necesidad de un tipo específico de pollos (15x7 ab+), uso de un gran número de animales 
y de un método estadístico para comparar las respuestas lesiónales con las de las cepas control JM/102W y 
Md5. Debido a estas limitaciones no ha sido y no es probablemente usado en otros laboratorios. La 
comparación en el patotipado puede ser mejorada mediante la comparación de aislados de campo con cepas 
prototipo como las JM/102W, Md5 y 648A (American Type Culture Collection) o sus equivalentes. Los 
datos pueden ser generados mediante diferentes procedimientos in vivo que miden la inducción de tumores, 
enfermedad neurològica (por lesiones neoplásicas o no neoplásicas), o únicamente por criterios no 
neoplásicos (como el peso de los órganos linfoides o la replicación vírica). Los métodos basados en criterios 
neoplásicos, especialmente cuando son generados en pollos inmunizados de MD, probablemente se 
correlacionarán mejor con el método del ADOL y serán más relevantes en cuanto a la evolución de los virus 
de MD en el campo. En base a los datos de diferentes experimentos, se propone una modificación del 
método ADOL que utiliza menos animales y puede ser llevado a cabo en pollos SPF comerciales. El método 
modificado se basa en una comparación con el que mejor clasifica las cepas prototipo, y se espera que de 
resultados en general comparables con el método original. Otros criterios alternativos (ver abajo) también se 
evalúan como métodos primarios de patotipificación o como adjuntos a otros métodos de patotipificación. 
Se presentan las ventajas y desventajas de estos métodos alternativos.
